| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
100.91(B) |
| Last
Volume: |
21,280,549 |
Avg
Vol: |
11,944,728 |
| 52
Week Range: |
$44.7 - $69.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.3 |
| Insider 3/6 Months : 11.9 |
|
| Guru Rank Number : 97 |
| Guru Rank Value : 8.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
| Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
69,103 |
681,397 |
| Total Sell Value |
$0 |
$0 |
$4,525,215 |
$49,727,684 |
| Total People Sold |
0 |
0 |
3 |
6 |
| Total Sell Transactions |
0 |
0 |
3 |
12 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Plenge Robert M |
EVP, Chief Research Officer |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,143 |
15,182 |
|
- |
|
| Lenkowsky Adam |
EVP, Chief Commercial Officer |
• – – |
2024-03-10 |
4 |
D |
$53.79 |
$232,534 |
D/D |
(4,323) |
6,650 |
|
- |
|
| Lenkowsky Adam |
EVP, Chief Commercial Officer |
• – – |
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,569) |
9,885 |
|
- |
|
| Lenkowsky Adam |
EVP, Chief Commercial Officer |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,016 |
13,859 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2024-03-10 |
4 |
D |
$53.79 |
$734,180 |
D/D |
(13,649) |
60,279 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,705) |
70,053 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,388 |
80,256 |
|
- |
|
| Poole Ahn Amanda |
EVP, Chief Human Resources |
• – – |
2024-03-10 |
4 |
D |
$53.79 |
$73,961 |
D/D |
(1,375) |
2,424 |
|
- |
|
| Poole Ahn Amanda |
EVP, Chief Human Resources |
• – – |
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,659) |
3,400 |
|
- |
|
| Poole Ahn Amanda |
EVP, Chief Human Resources |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,458 |
4,841 |
|
- |
|
| Hickey Benjamin |
President, RayzeBio Org.Office |
• – – |
2024-02-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
91 |
|
-12% |
|
| Hickey Benjamin |
President, RayzeBio Org.Office |
• – – |
2024-02-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
780 |
|
-12% |
|
| Meyers Gregory Scott |
EVP, Chief Digital & Tech Off. |
• – – |
2024-02-01 |
4 |
D |
$48.67 |
$36,697 |
D/D |
(754) |
5,286 |
|
- |
|
| Meyers Gregory Scott |
EVP, Chief Digital & Tech Off. |
• – – |
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,543 |
6,040 |
|
- |
|
| Poole Ahn Amanda |
EVP, Chief Human ResourcesOffi |
• – – |
2024-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
164 |
|
-15% |
|
| Boerner Christopher S. |
Chief Executive Officer |
• – – |
2023-12-05 |
4 |
B |
$49.78 |
$99,560 |
D/D |
2,000 |
82,672 |
2.74 |
-4% |
|
| Boerner Christopher S. |
Chief Executive Officer |
• – – |
2023-12-02 |
4 |
D |
$50.10 |
$67,635 |
D/D |
(1,350) |
80,672 |
|
- |
|
| Boerner Christopher S. |
Chief Executive Officer |
• – – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,638 |
82,022 |
|
- |
|
| Plenge Robert M |
EVP, Chief Research Officer |
• – – |
2023-12-02 |
4 |
D |
$50.10 |
$13,727 |
D/D |
(274) |
6,926 |
|
- |
|
| Plenge Robert M |
EVP, Chief Research Officer |
• – – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
616 |
7,200 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2023-12-02 |
4 |
D |
$50.10 |
$186,873 |
D/D |
(3,730) |
168,612 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
172,342 |
|
- |
|
| Boerner Christopher S. |
Chief Executive Officer |
• – – |
2023-11-28 |
4 |
B |
$48.86 |
$150,049 |
D/D |
3,071 |
79,384 |
2.74 |
5% |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2023-11-21 |
4 |
A |
$48.75 |
$479,163 |
I/I |
9,830 |
93,436 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2023-11-21 |
4 |
D |
$48.75 |
$479,163 |
D/D |
(9,830) |
331,414 |
|
- |
|
2225 Records found
|
|
Page 2 of 89 |
|
|
0.15 (0.34%) 
